TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04532034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Delivered Decision Support Intervention
Description: An intervention provided by a trained peer interventionist to facilitate treatment decision making among emerging adults with early psychosis. Specific components of this intervention may include facilitating access to information, clarifying values, helping a person obtain the needed support to make a decision, and screening for implementation barriers. Due to having lived experience of a mental health condition, the peer interventionist will also be able to provide unique types of information and support within the coaching process.
Study: NCT01406548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804 20mg/Kg
Study: NCT02204891

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics in SIBO
Description: Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: One capsule twice daily for 30 days
Study: NCT05888168

Intervention type: PROCEDURE
Intervention: CABG
Description: All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.

Intervention type: PROCEDURE
Intervention: CABG
Description: All participants in the study will undergo the standard procedure of CABG. Continuous electrocardiogram monitoring and electrocardiography were used to identify the cardiac rhythm.
Study: NCT04055857

Intervention type: OTHER
Description: There is no Intervention.

Intervention type: OTHER
Description: There is no Intervention.
Study: NCT04970758

Intervention type: OTHER
Description: no intervention
Study: NCT02507414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: 15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of microcirculation
Description: Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
Study: NCT02699320

Intervention type: OTHER
Intervention: Complications
Description: Not involved

Intervention type: OTHER
Intervention: Complications
Description: Not involved

Intervention type: OTHER
Intervention: Complications
Description: Not involved

Intervention type: OTHER
Intervention: Complications
Description: Not involved
Study: NCT01922908

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC Infusion
Description: Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Normal saline
Study: NCT01451385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV795
Description: COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)
Study: NCT03897660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 + vitamin K2 (TG form of omega-3)
Description: The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 + vitamin K2 (EE form of omega-3)
Description: The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]
Description: The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning.
Study: NCT02624453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral therapy
Description: First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Description: First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
Study: NCT02209701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfiromycin
Study: NCT01514201

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study: NCT02507414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head down tilt
Description: At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)
Study: NCT00401765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
Study: NCT02103829

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention #1
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #1
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #1
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
Study: NCT04255823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General practitioner and Patient receive informations related to PPI deprescribing.
Description: General practitioner will receive a sensibilization and an algorithm related to PPI deprescribing.~Their patients will receive any informations (patient information material on PPI deprescribing)
Study: NCT02103829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #1
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #2
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #2
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #3
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention #3
Description: Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
Study: NCT00643370

Intervention type: OTHER
Intervention: CT scan of the chest under deep inspiration breath hold
Description: computed tomography scan of the chest under dep inspiration breath hold conditions
Study: NCT04054687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
Study: NCT02612532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCIVA breath sampler
Description: Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
Study: NCT03365674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration applied with vibrator switch-on state (100Hz)
Study: NCT01514201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT03365674

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vibration
Description: Vibrator applied with switch-off state
Study: NCT01406548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804 20mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804 20mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 20mg/Kg BPS804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 20mg/Kg BPS804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 20mg/Kg BPS804
Study: NCT06243679

Intervention type: DRUG
Intervention: Immunotherapy
Description: Monotherapy with PD-1 inhibitors, up to 1 year.
Study: NCT03534856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Short guided mindfulness meditations were provided on an MP3 player.
Study: NCT01561066

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous platelet-rich fibrin glue (PRFG)
Description: 1. Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~2. PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: subcutaneous injection, 0.3mg/8h until enteral nutrition resolution

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Octreotide
Description: subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
Study: NCT02790346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthrodesis talonavicular

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tendon gestures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tendon gestures
Study: NCT04892576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The control group recieved the standard physical rehabilitation program conducted for 45 minutes, twice a week for eight consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.~The SSC group received the same program in addition to the SSC exercises for 30 minutes, two times per week for eight successive weeks
Study: NCT04255823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Only General practitioner receive informations related to PPI deprescribing.
Description: General practitioner will receive the sensibilization and an algorithm related to PPI deprescribing.~Their patients will not receive any informations.
Study: NCT03788278

Intervention type: DEVICE
Intervention: BioBeat
Description: The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.

Intervention type: DEVICE
Intervention: BioBeat
Description: The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
Study: NCT01728090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand sanitizer
Description: alcohol-based, hydroalcoholic gel
Study: NCT01301183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhIGF-1 with transdermal 17-beta estradiol
Description: RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and transdermal 17-beta estradiol
Description: Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
Study: NCT00997152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-654
Description: Tablets
Study: NCT03588637

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03348358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quiet music
Description: playing quiet music during labor
Study: NCT00997152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-654
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JTT-654 Placebo
Description: Tablets
Study: NCT03308500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent games
Description: The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
Study: NCT03780673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 20 mg/day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 400/8 hours for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Simvastatin
Description: Placebo of Simvastatin once a day for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Rifaximin
Description: Placebo of Rifaximin/8 hours for 12 months
Study: NCT03779373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of a decision support system on the EV1000 monitor (AFM mode)
Description: The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of a decision support system on the EV1000 monitor (AFM mode)
Description: The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
Study: NCT02127866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259 plus Foster 100/6 µg
Description: Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259 plus Foster 100/6 µg
Description: Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259 plus Foster 100/6 µg
Description: Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster 100/6 µg
Description: Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
Study: NCT02711085

Intervention type: OTHER
Intervention: No intervention
Description: No intervention - observational study
Study: NCT02799576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curved needle
Description: In this arm, the curved block needle will be used for regional blockade
Study: NCT05353920

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: cognitive related training bu virtual reality system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: cognitive related training bu virtual reality system
Study: NCT03142230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal
Description: The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier
Description: The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier